Feasibility of Hyivy Device Post-Radiation for Pelvic Malignancies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-11

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vaginal dilator therapy (VDT) with static dilators is often prescribed to patients following vaginal or pelvic radiation therapy. This study seeks to evaluate the feasibility of a novel intravaginal device that delivers patient-controlled dilation (Hyivy device). The study is designed as a proof-of-concept single-arm pilot study. The primary objective is to assess safety and tolerability, while also evaluating changes in health-related quality of life and pelvic pain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vaginal Dilator Therapy After Pelvic Radiation

NCT07216456

Pelvic Radiotherapy Vaginal Stenosis Pelvic Cancer +3 more

NOT_YET_RECRUITING NA

An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis

NCT03876860

Endometrial Cancer Cervical Cancer Vaginal Stricture +1 more

UNKNOWN NA

Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer

NCT00735514

Cervical Cancer Endometrial Cancer Radiation Toxicity +1 more

COMPLETED

Longitudinal Evaluation Study of Vaginal Stenosis With and Without Pelvic Radiation Therapy

NCT01404728

Malignancies Stenosis of Vagina

COMPLETED

Quantifying Radiation Induced Vaginal Stenosis

NCT05002751

Vaginal Stricture Vaginal Stenosis

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Radiation therapy is a common treatment for cancer in the pelvic area and is considered a mainstay of treatment for cancers of the cervix, uterus, and anorectum. Patients with a vagina and vaginal canal who undergo vaginal or pelvic radiation therapy are at risk for developing vaginal stenosis, defined in part by a shortening and/or narrowing of the vaginal canal, which can lead to damaged tissue and pain with examination/vaginal penetration.

Vaginal dilator therapy (VDT) is prescribed to prevent vaginal stenosis. Adherence to VDT in the months following radiation is quite low. Reasons may include limited size options of static dilators, lack of time, general fatigue, emotional well-being, and associating dilator use with underlying malignancy and radiation treatment. Alternatives to static dilators that are safe and effective may improve adherence to VDT and improve patient quality of life.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vaginal Stenosis Radiation Therapy Cancer Pelvic Pain Pelvic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

A prospective single-arm pre/post repeated-measures pilot study

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hyivy Intravaginal Device

Participants will receive a Hyivy intravaginal device for at-home use. Recommended use is three times per week for 12 weeks and consists of 10 minutes of heat (37-39ºC) and 10 minutes of dilation per session.

Group Type EXPERIMENTAL

Hyivy Intravaginal Device

Intervention Type DEVICE

Intravaginal use of Hyivy device three times per week for 12 weeks, with each session consisting of 10 minutes of heat (37-39ºC) and 10 minutes of dilation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hyivy Intravaginal Device

Intravaginal use of Hyivy device three times per week for 12 weeks, with each session consisting of 10 minutes of heat (37-39ºC) and 10 minutes of dilation.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1.Age ≥ 18 at the time of enrollment
* 2.Patient with a vagina or vaginal canal who have completed radiation therapy (either external beam or brachytherapy, or a combination of both) for endometrial cancer, cervical cancer, anal cancer, or rectal cancer, without concomitant chemotherapy
* 3.Generally in good health (other than due to cancer), at the discretion of the investigator(s)
* 4.Eastern Cooperative Oncology Group (ECOG) score or 0 to 2
* 5.Participants must be post-menopausal (natural or surgically) for at least 1 year prior to screening or be surgically sterile (absence of ovaries and/or uterus); or, a participant of child-bearing potential must agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months.
* 6.Agree not to use other dilators for the 12-week intervention period
* 7.Must have the ability to charge the investigational device
* 8.Must be willing and able to insert intravaginal device
* 9.Able to understand, comply and consent to protocol requirements and instructions
* 10.Able to attend scheduled study visits and complete required investigations
* 11.Ability to understand and willingness to sign written informed consent

Exclusion Criteria

* 1.Participants who are pregnant or planning to become pregnant during the trial
* 2.Any major surgery in the past 3 months unless post-surgery dilator use is recommended by a physician, or anticipates having a major surgery during the study
* 3.Any other medical condition or clinical finding giving reasonable suspicion of a disease or condition that contraindicates the use of the investigational product or that may affect the interpretation of the results or leave the patient at high risk from treatment complications, at the discretion of the investigator(s)
* 4.Allergy to Hyivy device's materials
* 5.Active pelvic or gynaecological infection
* 6.Current use of antibiotics for any infection
* 7.Have open wounds, cuts, or open sores present in the vaginal or pelvic area
* 8.Severe atrophic vaginitis or very dry, itchy, or sore vagina/vaginal area, at the discretion of the investigator(s)
* 9.Hypoesthesia or loss in sensation of the pelvic floor
* 10.Total and/or partial prolapse of the uterus and/or vagina
* 11.Symptoms of severe urinary retention, severe extra-urethral incontinence, or overflow incontinence
* 12.Unable to position the device according to directions for use
* 13.Use of any medical devices that may interfere with the investigational device's function, such as pacemakers, ventilators, and ear implants

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No